People with Neurological
Deaths from Neurological
Disorders each Year
Combined Economic Burden in Europe and the USA alone
Most brain disorders lack a biomarker (i.e, a way to measure disease progression). As a result, clinicians rely on subjective scales to measure efficacy of treatment which typically result in increased costs, poor patient outcomes, and years of time spent trying to find the right treatment.
A recent study showed that in the USA, direct costs related to Epilepsy have almost doubled in the last decade to $28B per year, while outcomes have not improved in almost three decades.
For Patients, it is even more difficult to be the 'eyes' of the clinicians outside of the clinic, particularly in trying to keep track of disease progression given the lack of knowledge of what to look for and if they are doing it well. Hear the perspective of Amy and David - parents of a child diagnosed with epilepsy.
Eysz is building a passive neurological exam using real world data. By leveraging oculometric data from consumer grade eye-tracking systems, our software algorithms have the potential to reliably detect consciousness and other neurological 'vital signs' such as cognition and mood. While our initial focus will be Epilepsy, our aim is to expand to other neurological disorders.
By helping clinicians get the data they need to identify the right treatments sooner.
Relieving patients and caregivers from the burden of self-reporting.
Reduce the number of costly visits to the hospital.
We completed a 30 patient proof-of-concept study which demonstrated that eye-tracking could be used to detect the subtlest seizure type, absence seizures.
Detecting Absence Seizures using Eye-tracking (DASEY): We have completed an in-depth clinical study supported by an NIH Phase 1 SBIR Grant involving 4 Level 4 Epilepsy Centers to analyze ictal eye-movement data and develop algorithms.
Supported by an NSF Phase 1 SBIR Grant we analyzed interictal eye-movement data and were able to show a correlation to subjects having active seizures.
We have been awarded an NIH SBIR Phase I grant to compare the accuracy of 3 epileptologists reading a smartphone video recording during hyperventilation to 3 epileptologists reading the corresponding video EEG during hyperventilation. We are currently recruiting for this study. More information can be found here.
We have been awarded an SBIR Phase II grant from the National Science Foundation (NSF) for assessing comorbidities in epilepsy using eye movement recordings. Stay tuned for more information on this study!
Neurologist with dual certification in epilepsy and neurology with over 10 years’ experience directing the clinical epilepsy and research programs at UCSF Benioff Children’s Hospital, Oakland
Leads our Product Development efforts and GTM Strategy. Brings 15+ Years Medical Device Experience in Product and Project Management, Product Launch, and Alliances having worked at Siemens Healthineers, Varian, and Omnicell.
Leads our eye-tracking research efforts . He completed his undergraduate degree in computer science and has deep experience applying machine learning methods. His PhD from UCSD focused on extracting signals from a complex medium.
Leads the design and implementation efforts for our eye-tracking data science experiements. Brings experience in research, statistical analysis, and computational modeling in the field of cognitive neurosicience —most recently as a postdoctoral researcher in the Cognitive Development Lab at the Ohio State University.
Supports the design and implementation of our eye-tracking data science experiments. Completed her Ph.D. from The Ohio State University in cognitive psychology, focusing on visual perception research with psychophysics and statistical modeling.
Driving initial roll-out and deployment initiatives to help Eysz transition from Idea Market Fit to Product Market Fit. She brings 5 years experience as a social worker holding various roles in a clinical care setting. She is currently pursing a Masters of Management in Clinical Informatics at Duke University.
Maslah Saul MD Professor Neurology and Director of the Stanford Epilepsy Center
Mark Loughridge and Michele Williams Professor of Neurology and Director, Yale Clinical Neuroscience Imaging Center
Head Neuropsychologist, Epilepsy at UCSF Benioff Children’s Hospital Oakland
Assistant Professor, Pediatrics - Pediatric Neurology at University of Alabama, Birmingham
Assistant Professor of Pediatrics -
Pediatric Neurology | Medical Director Pediatric Epilepsy Monitoring Unit | Section Head Pediatric Epilepsy, Vanderbilt University Medical Center
Associate Professor of Pediatrics - Pediatric Neurology | Assistant Division Director for Research, Pediatric Neurology, Atrium Health/Levine Children’s Hospital
Clinical Professor - Department of Neurosciences at University of California, San Diego; Medical Director of the Comprehensive Epilepsy Center at Rady Children’s Hospital
20+ years experience in R&D including eye-tracking software and hardware development. Previous CTO of Eyefluence, (acquired by Google)
20+ years experience in medical device go-to-market strategies. Currently Senior Director Marketing Americas at Varian Medical Systems, a Siemens Healthineers company.
20+ years experience in commercialization of software as medical devices. Previous Senior Director for M&A Integration at Varian Medical Systems (acquired by Siemens Healthineers)
20+ years experience in Executive Management and Board Management. Currently serves as a Partner for Ventac Partners and a Senior Advisor for Mesa Partners. He is also a parent of a child with epilepsy.
15+ years experience in Digital Health and Pharma. Currently Head of Digital Transformation Neurology at UCB Pharma, a global leader in the field of epilepsy research and medicine development.